MYTSYK, Yulian, Yosyf NAKONECHNYI, Victor DOSENKO, Pawel KOWAL, Michal PIETRUS, Katarina GAZDIKOVA, Monika LABUDOVA, Martin CAPRNDA, Robert PROSECKÝ, Jozef DRAGASEK, Peter KRUŽLIAK and Roman DATS. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics. Clinical Biochemistry. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2023, vol. 116, June 2023, p. 120-127. ISSN 0009-9120. Available from: https://dx.doi.org/10.1016/j.clinbiochem.2023.04.011.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics
Authors MYTSYK, Yulian, Yosyf NAKONECHNYI, Victor DOSENKO, Pawel KOWAL, Michal PIETRUS, Katarina GAZDIKOVA, Monika LABUDOVA, Martin CAPRNDA, Robert PROSECKÝ (203 Czech Republic, belonging to the institution), Jozef DRAGASEK, Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution) and Roman DATS.
Edition Clinical Biochemistry, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2023, 0009-9120.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.800 in 2022
RIV identification code RIV/00216224:14110/23:00131199
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.clinbiochem.2023.04.011
UT WoS 001005720800001
Keywords in English Prostate cancer; Diagnostics; RNA; PCA3; TMPRSS2; ERG; HOXC6; DLX1; Urinary marker
Tags 14110116, 14110121, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/7/2023 09:08.
Abstract
Background: Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. To date, the role of the combined application of long non-coding RNAs (PCA3, DLX1, HOXC6, TMPRSS2:ERG) for obtaining the most accurate method of detection of PCa has not yet been comprehensively investigated.Methods: In total 240 persons were included in the retrospective study. Among them were 150 patients with confirmed PCa, 30 patients with benign prostatic hyperplasia, 30 patients with active chronic prostatitis and 30 healthy volunteers. In all patients, the urine samples were collected prior to biopsy or treatment. Polymerase chain reaction with reverse transcription was performed to detect the expression level of PCA3, HOXC6, DLX1 and the presence of the TMPRSS2:ERG transcript.Results: PCA3 was detected in urine samples in all cases. Using a PCA3 score of 56 allowed the differentiation between PCa and all other cases with a sensitivity of 61% and specificity of 96% (p < 0.001) while a PCA3 score threshold value of 50 resulted in a differentiation between clinically significant PCa (ISUP grades 2-5) and all other cases with a sensitivity of 93% and specificity of 93% (p < 0.001). The TMPRSS2:ERG expression in urine was detected exclusively in the group of patients with PCa and only in 16% of all cases.Conclusions: PCA3 score detected in urine demonstrated moderate sensitivity and good specificity in differenti-ation between PCa and non-PCa and high sensitivity and specificity in differentiation between clinically sig-nificant PCa and non-PCa.
PrintDisplayed: 23/7/2024 21:17